# Bone Biologics Corp (BBLG)

Source: https://www.quantisnow.com/company/BBLG
Generated: 2026-11-18T04:10:34.034Z

- Ticker: BBLG
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Industrial Specialties
- SEC CIK: 0001419554
- Website: bonebiologics.com

## About

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. Its NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. The company is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. Its platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. The company has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.

## Latest BBLG news and filings

- 2026-11-16 17:01 UTC [SEC Schedule 13G] [SEC Form SCHEDULE 13G filed by Bone Biologics Corp](https://www.quantisnow.com/insight/sec-form-schedule-13g-filed-by-bone-biologics-corp-6793397)
- 2026-11-10 22:47 UTC [SEC Schedule 13G] [Amendment: SEC Form SCHEDULE 13G/A filed by Bone Biologics Corp](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-bone-biologics-corp-6784805)
- 2026-10-26 21:00 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Bone Biologics Corp](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-bone-biologics-corp-6757922)
- 2026-10-13 14:07 UTC [SEC Form 25-NSE filed by Bone Biologics Corp](https://www.quantisnow.com/insight/sec-form-25-nse-filed-by-bone-biologics-corp-6744655)
- 2026-09-30 21:14 UTC [SEC Form 4] [SEC Form 4 filed by Director Gagnon Robert E.](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-gagnon-robert-e-6730958)
- 2026-09-30 21:12 UTC [SEC Form 4] [SEC Form 4 filed by Director Angle Siddhesh Rajendra](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-angle-siddhesh-rajendra-6730950)
- 2026-09-30 21:09 UTC [SEC Form 4] [SEC Form 4 filed by Director Meikle Phillip Terry Ii](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-meikle-phillip-terry-ii-6730933)
- 2026-09-30 21:06 UTC [SEC Form 4] [SEC Form 4 filed by Director Stroever Bruce](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-stroever-bruce-6730926)
- 2026-09-29 21:00 UTC [SEC Form 8-K] [SEC Form 8-K filed by Bone Biologics Corp](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-bone-biologics-corp-6729489)
- 2026-09-16 21:00 UTC [SEC Form 8-K] [SEC Form 8-K filed by Bone Biologics Corp](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-bone-biologics-corp-6717871)
- 2026-09-08 12:30 UTC [Conference Announcement] [Bone Biologics Expands Trial Sites](https://www.quantisnow.com/insight/bone-biologics-expands-trial-sites-6707643)
- 2026-09-03 12:30 UTC [Conference Announcement] [Bone Biologics to Participate in the  H.C. Wainwright 28th Annual Global Investment Conference](https://www.quantisnow.com/insight/bone-biologics-to-participate-in-the-hc-wainwright-28th-annual-6704390)
- 2026-08-28 21:27 UTC [SEC Form DEF 14A] [SEC Form DEF 14A filed by Bone Biologics Corp](https://www.quantisnow.com/insight/sec-form-def-14a-filed-by-bone-biologics-corp-6698737)
- 2026-08-18 21:00 UTC [SEC Form PRE 14A] [SEC Form PRE 14A filed by Bone Biologics Corp](https://www.quantisnow.com/insight/sec-form-pre-14a-filed-by-bone-biologics-corp-6687035)
- 2026-08-14 21:00 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Bone Biologics Corp](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-bone-biologics-corp-6683596)
- 2026-08-12 12:00 UTC [Bone Biologics Achieves 32-Month Validated Shelf Life for rhNELL-1](https://www.quantisnow.com/insight/bone-biologics-achieves-32-month-validated-shelf-life-for-rhnell-1-6677057)
- 2026-07-27 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Bone Biologics Corp](https://www.quantisnow.com/insight/sec-form-effect-filed-by-bone-biologics-corp-6648837)
- 2026-07-24 21:00 UTC [SEC Form 424B3] [SEC Form 424B3 filed by Bone Biologics Corp](https://www.quantisnow.com/insight/sec-form-424b3-filed-by-bone-biologics-corp-6648594)
- 2026-07-23 12:05 UTC [SEC Form 8-K] [Bone Biologics Corp filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/bone-biologics-corp-filed-sec-form-8-k-regulation-fd-disclosure-6646367)
- 2026-07-23 12:00 UTC [Bone Biologics Issues Mid-Year Shareholder Update Highlighting Progress Across 2026 Priorities](https://www.quantisnow.com/insight/bone-biologics-issues-mid-year-shareholder-update-highlighting-progress-across-2026-6646310)
- 2026-07-20 21:15 UTC [SEC Form DEFA14A] [SEC Form DEFA14A filed by Bone Biologics Corp](https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-bone-biologics-corp-6642755)
- 2026-07-17 21:14 UTC [SEC Form S-3] [SEC Form S-3 filed by Bone Biologics Corp](https://www.quantisnow.com/insight/sec-form-s-3-filed-by-bone-biologics-corp-6641403)
- 2026-07-16 21:25 UTC [SEC Form 8-K] [Bone Biologics Corp filed SEC Form 8-K: Other Events](https://www.quantisnow.com/insight/bone-biologics-corp-filed-sec-form-8-k-other-events-6640166)
- 2026-07-09 20:30 UTC [SEC Form 8-K] [Bone Biologics Corp filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/bone-biologics-corp-filed-sec-form-8-k-entry-into-a-6633212)
- 2026-07-08 00:00 UTC [Bone Biologics Announces up to $9.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules](https://www.quantisnow.com/insight/bone-biologics-announces-up-to-90-million-private-placement-priced-6630656)
- 2026-07-02 12:01 UTC [SEC Form DEFA14A] [SEC Form DEFA14A filed by Bone Biologics Corp](https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-bone-biologics-corp-6624267)
- 2026-07-02 12:00 UTC [SEC Form DEF 14A] [SEC Form DEF 14A filed by Bone Biologics Corp](https://www.quantisnow.com/insight/sec-form-def-14a-filed-by-bone-biologics-corp-6624265)
- 2026-05-19 12:00 UTC [Bone Biologics Achieves 29-Month Validated Shelf Life for rhNELL-1](https://www.quantisnow.com/insight/bone-biologics-achieves-29-month-validated-shelf-life-for-rhnell-1-6561687)
- 2026-05-14 21:00 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Bone Biologics Corp](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-bone-biologics-corp-6554700)
- 2026-03-13 20:35 UTC [SEC Form 8-K] [Bone Biologics Corp filed SEC Form 8-K: Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/bone-biologics-corp-filed-sec-form-8-k-other-events-financial-6447269)
- 2026-03-13 20:31 UTC [SEC Form 424B5] [SEC Form 424B5 filed by Bone Biologics Corp](https://www.quantisnow.com/insight/sec-form-424b5-filed-by-bone-biologics-corp-6447241)
- 2026-03-02 21:35 UTC [SEC Form 10-K] [SEC Form 10-K filed by Bone Biologics Corp](https://www.quantisnow.com/insight/sec-form-10-k-filed-by-bone-biologics-corp-6422368)
- 2026-01-21 21:37 UTC [SEC Form 4] [SEC Form 4 filed by Chief Financial Officer Walsh Deina H](https://www.quantisnow.com/insight/sec-form-4-filed-by-chief-financial-officer-walsh-deina-6356432)
- 2026-01-21 21:37 UTC [SEC Form 4] [SEC Form 4 filed by Chief Executive Officer Frelick Jeff](https://www.quantisnow.com/insight/sec-form-4-filed-by-chief-executive-officer-frelick-jeff-6356431)
- 2026-01-08 13:05 UTC [SEC Form 8-K] [Bone Biologics Corp filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/bone-biologics-corp-filed-sec-form-8-k-regulation-fd-disclosure-6342297)
- 2026-01-08 13:00 UTC [Public Offering] [Bone Biologics Highlights 2025 Key Operational, Scientific, and Corporate Milestones and Provides 2026 Outlook](https://www.quantisnow.com/insight/bone-biologics-highlights-2025-key-operational-scientific-and-corporate-milestones-6342254)
- 2025-12-23 13:00 UTC [Bone Biologics Improves Extension of rhNELL-1 Product Shelf Life to 24 Months](https://www.quantisnow.com/insight/bone-biologics-improves-extension-of-rhnell-1-product-shelf-life-to-6326206)
- 2025-11-14 21:36 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Bone Biologics Corp](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-bone-biologics-corp-6281050)
- 2025-09-26 21:00 UTC [SEC Form S-8] [SEC Form S-8 filed by Bone Biologics Corp](https://www.quantisnow.com/insight/sec-form-s-8-filed-by-bone-biologics-corp-6213271)
- 2025-09-04 11:05 UTC [SEC Form 8-K] [Bone Biologics Corp filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/bone-biologics-corp-filed-sec-form-8-k-regulation-fd-disclosure-6189207)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/BBLG
- Earnings history: https://www.quantisnow.com/earnings/BBLG
- Dividend history: https://www.quantisnow.com/dividends/BBLG
- Insider transactions: https://www.quantisnow.com/insiders/BBLG
- Options chain: https://www.quantisnow.com/options/BBLG
- SEC 8-K filings only: https://www.quantisnow.com/company/BBLG/8-k
- RSS and alerts for BBLG: https://www.quantisnow.com/docs/rss-feeds.md
